Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure


Stojanovic K. S., Delmas Y., Torres P. U., Peltier J., Pelle G., Jeru I., ...Daha Fazla

NEPHROLOGY DIALYSIS TRANSPLANTATION, cilt.27, sa.5, ss.1898-1901, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 5
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1093/ndt/gfr528
  • Dergi Adı: NEPHROLOGY DIALYSIS TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1898-1901
  • Anahtar Kelimeler: AA amyloidosis, colchicine, familial Mediterranean fever, interleukine-1 inhibitors, renal failure, COLCHICINE, TOXICITY
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Background. Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disorder, for which systemic AA amyloidosis is the major complication revealed most of the time by renal abnormalities. Current treatment is daily colchicine that prevents both recurrent inflammatory attacks and amyloidosis deposition in most patients. However, some patients still develop amyloidosis and renal failure. Functional studies suggest that interleukin (IL)-1 is implicated in the inflammatory reaction in FMF and therefore, IL-1 inhibitors could be a new approach to treat FMF. The aim of this series study was to evaluate anakinra in patients with FMF complicated with amyloidosis and renal failure.